These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22111227)

  • 21. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
    Izumi K; Mizokami A; Namiki M
    Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Osteoporosis due to androgen suppression therapy in men with prostate cancer].
    Roux C
    Prog Urol; 2003 Apr; 13(2 Suppl 1):24-7. PubMed ID: 12815806
    [No Abstract]   [Full Text] [Related]  

  • 23. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 24. Re: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.
    Miró C; De Cobelli O; Orecchia R; Sancho G; Villavicencio H; Craven-Bartle J
    J Urol; 2002 Aug; 168(2):662-3; author reply 663. PubMed ID: 12131341
    [No Abstract]   [Full Text] [Related]  

  • 25. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 26. The impact of osteoporosis in men treated for prostate cancer.
    Oefelein MG; Resnick MI
    Urol Clin North Am; 2004 May; 31(2):313-9. PubMed ID: 15123410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of treatment-related osteoporosis in men with prostate cancer.
    Smith MR
    Cancer Treat Rev; 2003 Jun; 29(3):211-8. PubMed ID: 12787715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS
    Nat Clin Pract Urol; 2008 Jan; 5(1):24-34. PubMed ID: 18185511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Editorial comment.
    Shepard DR
    Urology; 2010 May; 75(5):1137. PubMed ID: 20451735
    [No Abstract]   [Full Text] [Related]  

  • 30. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer.
    Smith MR
    Cancer Metastasis Rev; 2002; 21(2):159-66. PubMed ID: 12465755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone Health in Men with Prostate Cancer: Review Article.
    A M El Badri S; Salawu A; Brown JE
    Curr Osteoporos Rep; 2019 Dec; 17(6):527-537. PubMed ID: 31760582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium supplements in patients with prostate cancer.
    Molokwu CN
    BJU Int; 2007 Dec; 100(6):1411. PubMed ID: 17979937
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hot flushes in men after surgical or pharmacologic castration].
    Aubert J; Vigouroux V; Doré B
    Prog Urol; 1995 Sep; 5(4):507-9. PubMed ID: 7581499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen Deprivation Therapy-Linked Cardiovascular Disease Risk: Still Unresolved.
    Azvolinsky A
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341000
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Compliance with hormonal treatment for prostate cancer.
    Kaisary AV
    Br J Hosp Med; 1996 Mar 20-Apr 2; 55(6):359-66. PubMed ID: 8696636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM; Pasini J; Mareković Z
    Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use.
    Cançado BL; Miranda LC; Madeira M; Farias ML
    Rev Col Bras Cir; 2015; 42(1):62-6. PubMed ID: 25992703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy.
    Pitts WR
    J Urol; 2005 May; 173(5):1829; author reply 1829-30. PubMed ID: 15821604
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.